258 related articles for article (PubMed ID: 27137986)
1. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
Li J; Lu S; Lombardo K; Monahan R; Amin A
Hum Pathol; 2016 Sep; 55():17-23. PubMed ID: 27137986
[TBL] [Abstract][Full Text] [Related]
2. p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
Acosta AM; Barletta J; Sonpavde G; Schnitt S; Hirsch MS
Arch Pathol Lab Med; 2021 Aug; 145(8):1000-1008. PubMed ID: 33237989
[TBL] [Abstract][Full Text] [Related]
3. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
4. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
Shah TS; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff DJ; Chen G; Warrick JI
Hum Pathol; 2017 Mar; 61():90-96. PubMed ID: 27818288
[TBL] [Abstract][Full Text] [Related]
6. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
Luo JH; Xie D; Liu MZ; Chen W; Liu YD; Wu GQ; Kung HF; Zeng YX; Guan XY
Int J Cancer; 2008 Jun; 122(11):2554-61. PubMed ID: 18246597
[TBL] [Abstract][Full Text] [Related]
7. Expression of transcription factor Twist1 in bladder urothelial carcinoma and its clinical significance.
Tang X; Xing J; Li W; Wu Z; Zhang K; Zheng J
J BUON; 2013; 18(1):211-9. PubMed ID: 23613408
[TBL] [Abstract][Full Text] [Related]
8. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
9. Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(3):3288-93. PubMed ID: 26045854
[TBL] [Abstract][Full Text] [Related]
10. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
11. Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder.
Paner GP; Cox RM; Richards K; Akki A; Gokden N; Lopez-Beltran A; Krausz T; McKenney JK; Steinberg GD
Am J Surg Pathol; 2014 Sep; 38(9):1251-9. PubMed ID: 25133708
[TBL] [Abstract][Full Text] [Related]
12. CD138 Expression Is Observed in the Urothelial Epithelium and in Various Urothelial Carcinomas, and Cannot Be Evidence for Plasmacytoid Urothelial Carcinoma.
Goto K
Int J Surg Pathol; 2016 Oct; 24(7):614-9. PubMed ID: 27305940
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of GATA-3 in urothelial carcinoma variants.
Liang Y; Heitzman J; Kamat AM; Dinney CP; Czerniak B; Guo CC
Hum Pathol; 2014 Jul; 45(7):1466-72. PubMed ID: 24745616
[TBL] [Abstract][Full Text] [Related]
15. Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder.
Keck B; Wach S; Kunath F; Bertz S; Taubert H; Lehmann J; Stöckle M; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Jul; 20(7):2440-5. PubMed ID: 23108554
[TBL] [Abstract][Full Text] [Related]
16. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
17. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
18. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the reduction of UT-B expression in urothelial carcinoma of the bladder.
Li C; Xue H; Lei Y; Zhu J; Yang B; Gai X
Pathol Res Pract; 2014 Dec; 210(12):799-803. PubMed ID: 25445116
[TBL] [Abstract][Full Text] [Related]
20. Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases.
Urrea YR; Epstein JI
Hum Pathol; 2017 Sep; 67():169-175. PubMed ID: 28827101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
